- Home
- EVMN vs DRUG Comparison
EVMN vs DRUG Comparison
Compare EVMN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVMN | DRUG |
|---|---|---|
| Founded | 2020 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 892.4M | 856.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | EVMN | DRUG |
|---|---|---|
| Price | $25.74 | $76.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $44.17 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 988.9K | 73.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.89 | $23.18 |
| 52 Week High | $33.20 | $123.75 |
Technical Indicators
Market Signals| Indicator | EVMN | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 43.83 |
| Support Level | $15.25 | $77.80 |
| Resistance Level | $33.20 | $91.00 |
| Average True Range (ATR) | 2.45 | 4.49 |
| MACD | -0.56 | -0.78 |
| Stochastic Oscillator | 37.93 | 26.42 |
Price Performance
Historical ComparisonAbout EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.